Janus Henderson Group PLC Galecto, Inc. Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.22 - $2.74 $883,918 - $1.99 Million	-724,523 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.72 - $3.31 $60,600 - $116,621	-35,233 Reduced 4.64%	724,523 $1.59 Million
Q4 2021 Feb 14, 2022	SELL	$2.3 - $3.58 $1.21 Million - $1.88 Million	-526,251 Reduced 40.92%	759,756 $2.3 Million
Q3 2021 Nov 16, 2021	SELL	$3.59 - $5.0 $48,454 - $67,485	-13,497 Reduced 1.04%	1,286,007 $4.5 Million
Q2 2021 Aug 16, 2021	SELL	$4.63 - $8.0 $103,827 - $179,400	-22,425 Reduced 1.7%	1,299,504 $6.41 Million

Q1 2021 May 17, 2021	SELL	$6.08 - $13.25 $82,931 - $180,730	-13,640 Reduced 1.02%	1,321,929 $7.83 Million
Q4 2020 Feb 16, 2021	BUY	$12.51 - $16.84 $16.7 Million - $22.5 Million	1,335,569 New	1,335,569 $15.9 Million

3.96M

30.6K

200

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $11.9M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.